Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs C2N 8E12 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Sponsors AbbVie
- 07 Dec 2018 Planned End Date changed from 19 Oct 2020 to 13 Nov 2020.
- 23 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 04 May 2018 Planned number of patients changed from 10 to 5.